Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease.
200 Barr Harbor Drive, Suite 400
West Conshohocken, PA 19428